JP2002543151A5 - - Google Patents

Download PDF

Info

Publication number
JP2002543151A5
JP2002543151A5 JP2000615040A JP2000615040A JP2002543151A5 JP 2002543151 A5 JP2002543151 A5 JP 2002543151A5 JP 2000615040 A JP2000615040 A JP 2000615040A JP 2000615040 A JP2000615040 A JP 2000615040A JP 2002543151 A5 JP2002543151 A5 JP 2002543151A5
Authority
JP
Japan
Prior art keywords
composition
polypeptide
antibody
composition according
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000615040A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002543151A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2000/012041 external-priority patent/WO2000066156A1/en
Publication of JP2002543151A publication Critical patent/JP2002543151A/ja
Publication of JP2002543151A5 publication Critical patent/JP2002543151A5/ja
Pending legal-status Critical Current

Links

JP2000615040A 1999-05-04 2000-05-04 死ドメイン含有レセプター５ Pending JP2002543151A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US13249899P 1999-05-04 1999-05-04
US60/132,498 1999-05-04
US13323899P 1999-05-07 1999-05-07
US60/133,238 1999-05-07
US14893999P 1999-08-13 1999-08-13
US60/148,939 1999-08-13
PCT/US2000/012041 WO2000066156A1 (en) 1999-05-04 2000-05-04 Death domain containing receptor 5

Publications (2)

Publication Number Publication Date
JP2002543151A JP2002543151A (ja) 2002-12-17
JP2002543151A5 true JP2002543151A5 (enExample) 2007-05-31

Family

ID=27384298

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000615040A Pending JP2002543151A (ja) 1999-05-04 2000-05-04 死ドメイン含有レセプター５

Country Status (5)

Country Link
EP (1) EP1196191A4 (enExample)
JP (1) JP2002543151A (enExample)
AU (1) AU4817200A (enExample)
CA (1) CA2369371A1 (enExample)
WO (1) WO2000066156A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7528239B1 (en) 1997-02-13 2009-05-05 Immunex Corporation Receptor that binds trail
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
US7476383B2 (en) 2000-05-02 2009-01-13 The Uab Research Foundation Antibody selective for DR4 and uses thereof
US7279160B2 (en) 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US7115717B2 (en) 2001-05-18 2006-10-03 Kirin Beer Kabushiki Kaisha Anti-TRAIL-R antibodies
US7064189B2 (en) 2001-05-25 2006-06-20 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
US7361341B2 (en) 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
JPWO2003038087A1 (ja) 2001-10-04 2005-02-24 関西ティー・エル・オー株式会社 ＤＲ５遺伝子のプロモーターおよびＳｉａｈ−１遺伝子のプロモーター
PT1606318E (pt) * 2003-03-26 2009-11-10 Deutsches Krebsforsch Proteínas de fusão de fc melhoradas
KR20060132006A (ko) 2004-03-23 2006-12-20 비오겐 아이덱 엠에이 아이엔씨. 수용체 커플링제 및 이의 치료적 용도
WO2005114187A2 (en) * 2004-04-23 2005-12-01 The United States Of America As Represented By Thesecretary, Department Of Health And Human Services Methods and compositions for diagnosing aids and other diseases and conditions involving immune system activation
JP5562521B2 (ja) 2005-02-02 2014-07-30 ザ ユーエービー リサーチ ファンデーション アポトーシス誘導デスレセプターアゴニストに対する抵抗性を低減することに関する薬剤及び方法
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
CA2780130A1 (en) 2009-11-05 2011-05-12 The Uab Research Foundation Treating basal-like genotype cancers
US8703712B2 (en) 2010-03-18 2014-04-22 The Uab Research Foundation Targeting cancer stem cells with DR5 agonists
JP6219923B2 (ja) * 2012-03-28 2017-10-25 アムジェン インコーポレイテッド Ｄｒ５受容体アゴニストの組み合わせ
WO2014159562A1 (en) 2013-03-14 2014-10-02 Bristol-Myers Squibb Company Combination of dr5 agonist and anti-pd-1 antagonist and methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010010924A1 (en) * 1997-03-14 2001-08-02 Keith Charles Deen Tumor necrosis factor related receptor, tr6 polynecleotides
JP4330180B2 (ja) * 1997-03-17 2009-09-16 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 死ドメイン含有レセプター５
EP1181319B1 (en) * 1999-05-28 2009-04-22 Genentech, Inc. Chimeric dr4 antibodies and uses thereof
ATE330972T1 (de) * 1999-06-09 2006-07-15 Genentech Inc Apo-2l rezeptor-agonist und cpt-11 synergie- effekt
TWI318983B (en) * 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof

Similar Documents

Publication Publication Date Title
JP2002543151A5 (enExample)
US20250313634A1 (en) Novel anti-pd-l1 antibodies
JP4764627B2 (ja) 新生物疾患又は免疫不全を処置するためのヒト化免疫調節性モノクローナル抗体
US10696745B2 (en) Anti-PD-L1 antibodies
AU2001295490B2 (en) Antibodies to human IL-1beta
US7786269B2 (en) Antibody to latent membrane proteins and uses thereof
US8470991B2 (en) Immunocytokine sequences and uses thereof
JP5179689B2 (ja) 抗体ベース融合タンパク質の循環系内半減期の増強
US7771723B2 (en) Remedies for myeloma to be used together with nitrogen mustard antitumor agents
EP0633931B1 (en) Monoclonal antibodies against the interferon receptor, with neutralizing activity against type i interferon
JP2002544172A5 (enExample)
CN112552399B (zh) 抗sars-cov-2中和抗体
CN111494626A (zh) 用于治疗il-4和/或il-13介导的信号转导相关的疾病的药物组合物
WO2011137687A1 (zh) 一种抗癌胚抗原抗体及其应用
CN106243225A (zh) 新型抗-pd-l1抗体
EP1159003B1 (en) Anti-tnf alpha antibodies in therapy of steroid resistant asthma
CA2240834C (en) Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines
CN121263449A (zh) Cd19/cd38多特异性抗体
JP2021536231A (ja) 融合タンパク質、並びに腫瘍及び／又はウイルス感染の治療薬を製造するためのその使用
US8679483B2 (en) High-yield method for the production of human antibodies blocking the biological activity of a human cytokine
CN113461817B (zh) 一种抗人cd47抗体及其抗原结合片段、制备方法和应用
Xiang et al. Targeting gamma interferon to tumor cells by a genetically engineered fusion protein secreted from myeloma cells
EP0783526A1 (en) Anti-receptor and growth blocking agents to the vitamin b12/transcobalamin ii receptor and binding sites
CN116063512B (zh) 多功能重组抗体及其制备方法和应用
KR20250127148A (ko) 항-인터류킨-6 항체 투여에 의한 심근염의 치료